Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta Limited announced that all resolutions at its Annual General Meeting were passed with over 98% support. The company is strategically positioned to dominate the high-growth cellular immunotherapy market, particularly in the treatment of solid tumors, leveraging its innovative approach and strategic partnerships.
More about AdAlta Ltd.
AdAlta Limited is a clinical stage biotechnology company focusing on cellular immunotherapies for treating solid cancers. The company leverages an ‘East to West’ strategy, integrating Asian T cell therapy innovations with Australia’s clinical and manufacturing strengths to connect Eastern innovations with Western markets. AdAlta specializes in in-licensing products from Asia, establishing US FDA regulated manufacturing, and conducting Phase I clinical studies, aiming to on-license products to larger biopharmaceutical companies. The company targets the underserved solid tumor segment, which constitutes 90% of cancers, and is projected to grow significantly. AdAlta’s AD-214, a fusion protein for fibrotic diseases, has shown efficacy in animal models and Phase I studies.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$7.57M
Learn more about 1AD stock on TipRanks’ Stock Analysis page.